WO2004019875A3 - Non-invasive methods to identify agents for treating pain - Google Patents

Non-invasive methods to identify agents for treating pain Download PDF

Info

Publication number
WO2004019875A3
WO2004019875A3 PCT/US2003/026890 US0326890W WO2004019875A3 WO 2004019875 A3 WO2004019875 A3 WO 2004019875A3 US 0326890 W US0326890 W US 0326890W WO 2004019875 A3 WO2004019875 A3 WO 2004019875A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
identify agents
treating pain
invasive methods
kits
Prior art date
Application number
PCT/US2003/026890
Other languages
French (fr)
Other versions
WO2004019875A2 (en
Inventor
Kenneth M Hargreaves
Karl Keiser
Original Assignee
Univ Texas
Kenneth M Hargreaves
Karl Keiser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Kenneth M Hargreaves, Karl Keiser filed Critical Univ Texas
Priority to AU2003273247A priority Critical patent/AU2003273247A1/en
Publication of WO2004019875A2 publication Critical patent/WO2004019875A2/en
Publication of WO2004019875A3 publication Critical patent/WO2004019875A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are improved methods, compositions and kits for use in testing pain responses and identifying analgesic and anesthetic substances. The non-invasive screening assays described use compositions and kits comprising peripheral neurons, particularly those including neurons previously sensitized to pain in an in vivo setting, as in vitro models for identify agents for inhibiting pain signaling and for improved efficacy in the clinical treatment of pain.
PCT/US2003/026890 2002-08-30 2003-08-27 Non-invasive methods to identify agents for treating pain WO2004019875A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273247A AU2003273247A1 (en) 2002-08-30 2003-08-27 Non-invasive methods to identify agents for treating pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40702502P 2002-08-30 2002-08-30
US60/407,025 2002-08-30

Publications (2)

Publication Number Publication Date
WO2004019875A2 WO2004019875A2 (en) 2004-03-11
WO2004019875A3 true WO2004019875A3 (en) 2006-07-27

Family

ID=31978408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026890 WO2004019875A2 (en) 2002-08-30 2003-08-27 Non-invasive methods to identify agents for treating pain

Country Status (2)

Country Link
AU (1) AU2003273247A1 (en)
WO (1) WO2004019875A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
SI3242676T1 (en) 2015-01-07 2024-02-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683725A (en) * 1995-05-25 1997-11-04 Biofrontiers, Inc. Modulation of substance P by compounds containing calcium sulfate and methods relating thereto
US20020034781A1 (en) * 2000-04-07 2002-03-21 Glucksmann Maria Alexandra 12303, a novel human TWIK molecule and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683725A (en) * 1995-05-25 1997-11-04 Biofrontiers, Inc. Modulation of substance P by compounds containing calcium sulfate and methods relating thereto
US20020034781A1 (en) * 2000-04-07 2002-03-21 Glucksmann Maria Alexandra 12303, a novel human TWIK molecule and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RIBEIRO S.A. ET AL.: "Antinociceptive action of bradykinin and related kinins of larger molecular weights by the intraventricular route", BR. J. PHARMACOL., vol. 47, no. 3, March 1973 (1973-03-01), pages 517 - 528, XP003002650 *
SABINO ET AL.: "Tooth extraction-induced internalization of the substance P receptor in trigeminal nucleus and spinal cord neurons: imaging the neurochemistry of dental pain", PAIN, vol. 95, no. 1-2, January 2002 (2002-01-01), pages 175 - 186 *

Also Published As

Publication number Publication date
WO2004019875A2 (en) 2004-03-11
AU2003273247A8 (en) 2004-03-19
AU2003273247A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
EP2006298A3 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2003087831A3 (en) Proteins involved in breast cancer
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
DE60312309D1 (en) USE OF BOTULINUM TOXIN TO TREAT HEART AND CIRCULAR DISEASES
DE602004010407D1 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
ATE399553T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DEXTROMETHORPHAN AND QUINIDENE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE602004016729D1 (en) 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ATE540129T1 (en) TARGET FOR THE THERAPY OF COGNITIVE DISABILITIES
WO2005052002A3 (en) Single-domain antibodies and uses thereof
EP1551990A4 (en) Diagnosis and treatment of chemoresistant tumors
WO2005089310A3 (en) Breath test for oral malodor
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
WO2005034889A3 (en) Method for imparting artificial tan to human skin
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1696933A4 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
TW200744628A (en) Stimulators of factor X activated (FXA) as new topical antihemorrhagic agents
WO2004019875A3 (en) Non-invasive methods to identify agents for treating pain
WO2004016751A3 (en) Methods of treating neurodegenerative diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003278497A8 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
DE602004030661D1 (en) USE OF KAHALALIDE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PSORIASIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP